{
    "title": "114_hr2338",
    "content": "Development and use of patient experience data to enhance risk-benefit assessment framework. The FDA is amending Section 505 of the Federal Food, Drug, and Cosmetic Act to implement a structured risk-benefit assessment framework in the new drug approval process. This framework aims to balance the consideration of benefits and risks and ensure consistent communication of the benefits and risks of new drugs. The FDA is implementing a structured risk-benefit assessment framework in the new drug approval process to balance and communicate the benefits and risks of new drugs. Patient experience data will be used to enhance this framework. Patient experience data, collected by various entities, will be used to enhance the structured risk-benefit assessment framework in the new drug approval process. The Secretary of Health and Human Services will publish guidance on implementing risk-benefit assessments for new drugs, specifying review timelines and data usage. The Secretary will use documents, data, or analyses to update guidance documents or publish new guidance. This includes guidance on collecting patient experience data, such as methods for gathering information on living with a disease. The curr_chunk discusses managing the impact of a disease on daily life, the effects of therapeutic options, establishing disease registries, assessing patient beliefs, and methodologies for patient-reported outcomes. The Secretary of Health and Human Services will issue guidance on implementing patient-reported outcomes within three years of the Act's enactment. Workshops will be held every six months to gather input on methodologies. A workshop will be held to gather input on methodologies for developing guidance on patient-reported outcomes, including patient experience data collection. Attendees will include patients, representatives from advocacy organizations, biopharmaceutical companies, disease research foundations, FDA reviewing divisions, and methodological experts. The Secretary of Health and Human Services will hold a public meeting within 90 days of publishing draft guidance to gather input on the guidance."
}